What is HC Wainwright’s Forecast for SABS Q2 Earnings?

SAB Biotherapeutics, Inc. (NASDAQ:SABS) – Stock analysts at HC Wainwright issued their Q2 2026 earnings per share estimates for SAB Biotherapeutics in a report released on Tuesday, May 12th. HC Wainwright analyst E. Bodnar forecasts that the company will post earnings per share of ($0.24) for the quarter. HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for SAB Biotherapeutics’ current full-year earnings is ($1.10) per share. HC Wainwright also issued estimates for SAB Biotherapeutics’ Q3 2026 earnings at ($0.26) EPS, Q4 2026 earnings at ($0.27) EPS, FY2026 earnings at ($1.10) EPS, FY2027 earnings at ($0.54) EPS, FY2028 earnings at ($0.42) EPS, FY2029 earnings at ($0.42) EPS and FY2030 earnings at ($0.43) EPS.

A number of other brokerages have also commented on SABS. Rodman & Renshaw reissued a “buy” rating and set a $13.00 price target on shares of SAB Biotherapeutics in a research note on Monday. Wall Street Zen lowered SAB Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 14th. Weiss Ratings reissued a “sell (d+)” rating on shares of SAB Biotherapeutics in a research note on Friday, April 10th. Zacks Research raised SAB Biotherapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday. Finally, Chardan Capital lifted their price target on SAB Biotherapeutics from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday, March 11th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, SAB Biotherapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $11.00.

SAB Biotherapeutics Stock Performance

Shares of SABS stock opened at $3.96 on Thursday. The business’s 50-day moving average price is $3.86 and its 200-day moving average price is $3.82. SAB Biotherapeutics has a 12 month low of $1.60 and a 12 month high of $6.60. The firm has a market capitalization of $201.76 million, a price-to-earnings ratio of -1.88 and a beta of 0.55. The company has a current ratio of 9.46, a quick ratio of 9.46 and a debt-to-equity ratio of 0.02.

SAB Biotherapeutics (NASDAQ:SABS) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.15).

Institutional Investors Weigh In On SAB Biotherapeutics

A number of hedge funds have recently added to or reduced their stakes in SABS. PNC Financial Services Group Inc. bought a new stake in SAB Biotherapeutics in the first quarter worth approximately $29,000. ADAR1 Capital Management LLC bought a new stake in SAB Biotherapeutics in the third quarter worth approximately $30,000. Dimensional Fund Advisors LP bought a new stake in SAB Biotherapeutics in the third quarter worth approximately $32,000. State of Wyoming bought a new stake in SAB Biotherapeutics in the fourth quarter worth approximately $34,000. Finally, Virtu Financial LLC bought a new stake in SAB Biotherapeutics in the third quarter worth approximately $40,000. 7.82% of the stock is currently owned by institutional investors.

SAB Biotherapeutics News Roundup

Here are the key news stories impacting SAB Biotherapeutics this week:

• Positive Sentiment: HC Wainwright raised its price target on SAB Biotherapeutics to $10 and reiterated a Buy rating, signaling more than 150% upside from recent levels and helping support sentiment around the stock.
• Positive Sentiment: The firm also published long-term earnings estimates that, while still negative, suggest a gradual improvement in losses over time, which may reassure investors that the company’s financial trajectory is improving.
• Positive Sentiment: Zacks Research upgraded SAB Biotherapeutics from Strong Sell to Hold, adding another constructive signal for the shares.
• Neutral Sentiment: SAB Biotherapeutics reported Q1 2026 EPS of ($0.35), missing the consensus estimate of ($0.20). The earnings miss is a fundamental headwind, but it was partially offset by investor focus on the company’s pipeline progress. SAB Biotherapeutics Q1 2026 earnings call
• Neutral Sentiment: Management said the registrational SAFEGUARD trial for SAB-142 is advancing, with enrollment expected to finish by the end of 2026 and topline data anticipated in 2H 2027, which supports the long-term pipeline story. SAB BIO Q1 2026 financial results and business highlights

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.